title: Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment.
abstract: OBJECTIVE
  The objective of this study was to develop a predictive algorithm for the likelihood of red blood cell transfusion in women with ovarian cancer undergoing platinum-based chemotherapy.
  
  
  METHODS
  Patients in this analysis came from two phase III studies conducted by the Southwest Oncology Group and Gynecologic Oncology Group of platinum-based chemotherapy in advanced ovarian cancer patients, SWOG 8412 and SWOG 8501/GOG 104. The probability of packed red blood cell (PRBC) transfusion was modeled as a function of stage of disease, age, weight, creatinine clearance, hemoglobin (Hb) prior to the start of therapy, the platinum agent administered (i.e., cisplatin vs carboplatin), and the route of drug administration (i.e., intravenous vs intraperitoneal).
  
  
  RESULTS
  Overall, 16% of patients developed at least grade 3 anemia (Hb < 8 g/dL) during primary chemotherapy, with 2% experiencing grade 4 anemia (Hb < 6.5 g/dL). PRBC transfusions were administered to 32% of patients. Factors that were determined to be predictive of PRBC transfusions were age and baseline Hb. In patients with bulky stage III or stage IV disease, the odds of transfusion increased by 66% for each 10-year increase in age and by 65% for each 1 g/dL decrease in baseline hemoglobin. Thus a patient aged 65 with a baseline Hb of 10.5 g/dL has approximately a 40% chance of transfusion.
  
  
  CONCLUSIONS
  Older ovarian cancer patients (>65 years) with low baseline Hb levels (<10.5) at initiation of platinum-based chemotherapy are likely to become more anemic during treatment and should be considered for prophylactic erythropoietin therapy as an alternative to transfusion.
authors.affiliation: Arizona Cancer Center, Tucson, AZ, USA.
authors.forename: David
authors.initials: D
authors.lastname: Heddens
authors.forename: David S
authors.initials: DS
authors.lastname: Alberts
authors.forename: Edward V
authors.initials: EV
authors.lastname: Hannigan
authors.forename: Steven D
authors.initials: SD
authors.lastname: Williams
authors.forename: Dava
authors.initials: D
authors.lastname: Garcia
authors.forename: Denise J
authors.initials: DJ
authors.lastname: Roe
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Bell
authors.forename: Ronald D
authors.initials: RD
authors.lastname: Alvarez
mesh_terms: D000368:Aged; D000465:Algorithms; D000740:Anemia / Q000139:chemically induced / Q000150:complications / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D017326:Clinical Trials, Phase III as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D017707:Erythrocyte Transfusion; D005260:Female; D006801:Humans; D008875:Middle Aged; D015233:Models, Statistical; D010051:Ovarian Neoplasms / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic
chemical_list: D003520:Cyclophosphamide; D016190:Carboplatin; D002945:Cisplatin